Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.58% | -18.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.12% | -23.33% | |||
| Operating Income | 14.12% | 23.33% | |||
| Income Before Tax | 91.97% | -11.11% | |||
| Income Tax Expenses | -68.26% | 28.99% | |||
| Earnings from Continuing Operations | 115.31% | -21.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 115.31% | -21.07% | |||
| EBIT | 14.12% | 23.33% | |||
| EBITDA | 14.13% | 23.34% | |||
| EPS Basic | 112.74% | -21.05% | |||
| Normalized Basic EPS | 93.35% | -11.13% | |||
| EPS Diluted | 112.74% | -21.05% | |||
| Normalized Diluted EPS | 93.35% | -11.13% | |||
| Average Basic Shares Outstanding | 20.20% | 0.00% | |||
| Average Diluted Shares Outstanding | 20.20% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||